Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Marie Y. Detrait(Hôpital Civil de Charleroi), Mauricette Michallet(Université Claude Bernard Lyon 1), Didier Blaise(Institut Paoli-Calmettes), L. Magro(Centre Hospitalier Universitaire de Lille), Nöel Milpied(Hôpital Cardiologique du Haut-Lévêque), Stéphane Morisset(Lyon 1 Université), Roberto Crocchiolo(Istituti di Ricovero e Cura a Carattere Scientifico), Fiorenza Barraco(Hôpital Lyon Sud), Patrice Chevalier(Centre Hospitalier Universitaire de Nantes), Ibrahim Yakoub‐Agha(Inserm), Nicole Raus, Reza Tabrizi(Université de Bordeaux), Régis Peffault de Latour(Hôpital Saint-Louis), J-O Bay(Centre Hospitalier Universitaire de Clermont-Ferrand), Gèrard Socié(Hôpital Saint-Louis), S. Vigouroux(Centre Hospitalier Universitaire de Bordeaux), Mohamad Mohty(Sorbonne Université)
Cited by 8
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
|Nature|2010|1.3k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Solid Cancers after Bone Marrow Transplantation
|New England Journal of Medicine|1997|968
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859